TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01048385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 concomitant treatment
Description: Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treated with capsules containing the vehicle (Sesame oil).
Study: NCT02705729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Universal
Description: High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Molar Quick
Description: High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
Study: NCT02279732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT02726074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Study: NCT02279732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03480009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Dextromethorphan capsule
Study: NCT03901092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flortaucipir F 18
Description: No study drug will be administered.
Study: NCT02123446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered orally.
Study: NCT02279732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01318031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1
Description: Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2
Description: Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
Study: NCT01912378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Study: NCT03396614

Intervention type: DIAGNOSTIC_TEST
Intervention: CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
Description: CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
Study: NCT02375191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study: NCT03206190

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture and blood draw
Description: Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI will be used to reveal presymptomatic brain morphology changes (not obligate)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
Study: NCT02375191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Study: NCT02422797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR
Description: CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
Study: NCT01708668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal-epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal-epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal-epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal-epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion
Study: NCT03480009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Dextromethorphan capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
Study: NCT01345682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Weekly
Study: NCT03197909

Intervention type: OTHER
Intervention: Determination of pro-inflammatory plasma factors
Description: Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old

Intervention type: OTHER
Intervention: Determination of pro-inflammatory plasma factors
Description: Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
Study: NCT02886559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide plus DCAG regimen
Description: chidamide, decitabine, aclarubicin, cytarabine and G-CSF
Study: NCT04672421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No device after laparoscopic surgery
Study: NCT02986815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]Acetate Brain Imaging
Description: Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the \[11C\]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
Study: NCT00507273

Intervention type: OTHER
Intervention: GIST Registry
Description: Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
Study: NCT00958217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy-Modified (CPT-M)
Description: Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Description: Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
Study: NCT00510978

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis 35624
Description: 1 sachet/day for one year

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius UCC118
Description: 1 sachet per day for 1 year

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet per day for 1 year
Study: NCT01949519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene and Docetaxel
Description: During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
Study: NCT04350307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge needle
Description: 22-gauge Quincke needle used for epidural injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge needle
Description: 22-gauge Quincke needle used for epidural injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25-gauge needle
Description: 25-gauge Quincke needle used for epidural injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25-gauge needle
Description: 25-gauge Quincke needle used for epidural injection
Study: NCT02495454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga101
Study: NCT00696969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B Deoxycholate
Description: 1 mg/kg e.o.d for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambisome + Miltefosine
Description: Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambisome and Paromomycin
Description: Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
Study: NCT02375191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT02596594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetal nutrition port system
Description: Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
Study: NCT01952756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: One tablet (100 mg) twice per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Placebo
Description: One tablet twice per day for 12 weeks
Study: NCT02059850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03967392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: TREATMENT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: TREATMENT
Study: NCT00228917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
Study: NCT03206190

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI will be used to reveal presymptomatic brain morphology changes (not obligate)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrophysiology
Description: Electrophysiological tests will be used to characterize patients better.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrophysiology
Description: Electrophysiological tests will be used to characterize patients better.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrophysiology
Description: Electrophysiological tests will be used to characterize patients better.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing functional performance
Description: By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing functional performance
Description: By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing functional performance
Description: By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non motor symptoms
Description: By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non motor symptoms
Description: By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non motor symptoms
Description: By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
Study: NCT01835964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose Variability Observation
Description: On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
Study: NCT03232151

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-Arm Cone Beam Computed Tomography
Description: C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
Study: NCT02279732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride injection, USP, or 5% dextrose injection
Study: NCT02991456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rolapitant
Description: single 180 mg dose by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rolapitant
Description: single 180 mg dose by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg by mouth daily
Study: NCT01317914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary instruction
Description: Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
Study: NCT04201275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA capsule
Description: Capsule administered orally once daily
Study: NCT00696969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine and Paromomycin
Description: Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
Study: NCT04107441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8 Part 1
Description: 5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8 Part 2
Description: 5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
Study: NCT02966470

Intervention type: DEVICE
Intervention: Obtain grip strength from a standardized gripometer
Description: Obtain grip strength from a standardized gripometer, 3 times on each hand
Study: NCT04201275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: HEC74647PA capsule matching placebo administered orally once daily
Study: NCT05456061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% diquafosol eyedrops
Description: Diquas® (Santen, Osaka, Japan), six times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% diquafosol eyedrops
Description: Diquas® (Santen, Osaka, Japan), six times per day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone punctal plug insertion
Description: a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone punctal plug insertion
Description: a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
Study: NCT01537497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
Study: NCT00321555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
Description: LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
Study: NCT03507179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3d printed denture
Description: construction of a 3d printed denture through a recent method instead of conventional processing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional dentures
Description: conventional dentures